March 5, 2024 07:13 AM ESTUpdated 12:22 PM
R&D

No­vo’s kid­ney dis­ease win for Ozem­pic adds to case for ex­pand­ed use in di­a­bet­ic pa­tients

Ayisha Sharma

News Reporter

No­vo Nordisk’s semaglu­tide sig­nif­i­cant­ly re­duced the risk of car­dio­vas­cu­lar events and death in pa­tients with type 2 di­a­betes and chron­ic kid­ney dis­ease in a late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times